annual cash & cash equivalents:
$58.53M+$359.00K(+0.62%)Summary
- As of today (July 1, 2025), TVTX annual cash & cash equivalents is $58.53 million, with the most recent change of +$359.00 thousand (+0.62%) on December 31, 2024.
- During the last 3 years, TVTX annual cash & cash equivalents has fallen by -$107.22 million (-64.69%).
- TVTX annual cash & cash equivalents is now -64.69% below its all-time high of $165.75 million, reached on December 31, 2021.
Performance
TVTX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$61.90M+$3.36M(+5.74%)Summary
- As of today (July 1, 2025), TVTX quarterly cash & cash equivalents is $61.90 million, with the most recent change of +$3.36 million (+5.74%) on March 31, 2025.
- Over the past year, TVTX quarterly cash & cash equivalents has increased by +$18.65 million (+43.11%).
- TVTX quarterly cash & cash equivalents is now -75.88% below its all-time high of $256.57 million, reached on March 31, 2022.
Performance
TVTX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TVTX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +0.6% | +43.1% |
| 3 y3 years | -64.7% | -75.9% |
| 5 y5 years | -6.3% | -7.6% |
TVTX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -64.7% | +0.6% | -65.6% | +91.7% |
| 5 y | 5-year | -64.7% | +0.6% | -75.9% | +91.7% |
| alltime | all time | -64.7% | >+9999.0% | -75.9% | >+9999.0% |
TVTX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $61.90M(+5.7%) |
| Dec 2024 | $58.53M(+0.6%) | $58.53M(+60.8%) |
| Sep 2024 | - | $36.41M(+12.8%) |
| Jun 2024 | - | $32.29M(-25.3%) |
| Mar 2024 | - | $43.25M(-25.7%) |
| Dec 2023 | $58.18M(-5.7%) | $58.18M(-59.7%) |
| Sep 2023 | - | $144.24M(+103.5%) |
| Jun 2023 | - | $70.87M(-56.1%) |
| Mar 2023 | - | $161.38M(+161.6%) |
| Dec 2022 | $61.69M(-62.8%) | $61.69M(-59.2%) |
| Sep 2022 | - | $151.34M(-15.8%) |
| Jun 2022 | - | $179.76M(-29.9%) |
| Mar 2022 | - | $256.57M(+54.8%) |
| Dec 2021 | $165.75M(+95.5%) | $165.75M(+10.3%) |
| Sep 2021 | - | $150.33M(+80.5%) |
| Jun 2021 | - | $83.29M(-43.8%) |
| Mar 2021 | - | $148.23M(+74.9%) |
| Dec 2020 | $84.77M(+35.8%) | $84.77M(-57.7%) |
| Sep 2020 | - | $200.48M(-15.5%) |
| Jun 2020 | - | $237.17M(+253.9%) |
| Mar 2020 | - | $67.02M(+7.3%) |
| Dec 2019 | $62.44M(-39.3%) | $62.44M(-4.2%) |
| Sep 2019 | - | $65.19M(-13.8%) |
| Jun 2019 | - | $75.66M(+8.3%) |
| Mar 2019 | - | $69.84M(-32.1%) |
| Dec 2018 | $102.87M(+3.5%) | $102.87M(-33.6%) |
| Sep 2018 | - | $154.82M(+73.4%) |
| Jun 2018 | - | $89.31M(+46.1%) |
| Mar 2018 | - | $61.12M(-38.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | $99.39M(+142.4%) | $99.39M(+0.4%) |
| Sep 2017 | - | $98.99M(+10.9%) |
| Jun 2017 | - | $89.27M(+113.2%) |
| Mar 2017 | - | $41.87M(+2.1%) |
| Dec 2016 | $41.00M(+8.5%) | $41.00M(+71.6%) |
| Sep 2016 | - | $23.89M(+13.0%) |
| Jun 2016 | - | $21.16M(-9.1%) |
| Mar 2016 | - | $23.26M(-38.5%) |
| Dec 2015 | $37.80M(+107.7%) | $37.80M(-73.1%) |
| Sep 2015 | - | $140.60M(+10.1%) |
| Jun 2015 | - | $127.75M(+6.3%) |
| Mar 2015 | - | $120.17M(+560.2%) |
| Dec 2014 | $18.20M(+203.5%) | $18.20M(-29.6%) |
| Sep 2014 | - | $25.86M(-35.2%) |
| Jun 2014 | - | $39.88M(+979.2%) |
| Mar 2014 | - | $3.70M(-38.4%) |
| Dec 2013 | $6.00M(>+9900.0%) | $6.00M(-55.3%) |
| Sep 2013 | - | $13.41M(+4580.6%) |
| Jun 2013 | - | $286.50K(-88.6%) |
| Mar 2013 | - | $2.50M(>+9900.0%) |
| Dec 2012 | $11.40K(+192.3%) | - |
| Nov 2012 | - | $3900.00(0.0%) |
| Aug 2012 | - | $3900.00(0.0%) |
| May 2012 | - | $3900.00(0.0%) |
| Feb 2012 | - | $3900.00(0.0%) |
| Feb 2012 | $3900.00(-2.5%) | - |
| Nov 2011 | - | $3900.00(0.0%) |
| Aug 2011 | - | $3900.00(-2.5%) |
| Feb 2011 | $4000.00 | $4000.00 |
FAQ
- What is Travere Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Travere Therapeutics?
- What is Travere Therapeutics annual cash & cash equivalents year-on-year change?
- What is Travere Therapeutics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Travere Therapeutics?
- What is Travere Therapeutics quarterly cash & cash equivalents year-on-year change?
What is Travere Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of TVTX is $58.53M
What is the all time high annual cash & cash equivalents for Travere Therapeutics?
Travere Therapeutics all-time high annual cash & cash equivalents is $165.75M
What is Travere Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, TVTX annual cash & cash equivalents has changed by +$359.00K (+0.62%)
What is Travere Therapeutics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of TVTX is $61.90M
What is the all time high quarterly cash & cash equivalents for Travere Therapeutics?
Travere Therapeutics all-time high quarterly cash & cash equivalents is $256.57M
What is Travere Therapeutics quarterly cash & cash equivalents year-on-year change?
Over the past year, TVTX quarterly cash & cash equivalents has changed by +$18.65M (+43.11%)